Single-cell RNA-Seq's (scRNA-Seq) unprecedented cellular resolution at a genome wide scale enables us to address questions about cellular heterogeneity that are inaccessible using methods that average over bulk tissue extracts.
Introduction
Compared to bulk RNA-Seq, where expression profiles are the result of averaging over millions of cells that may vary widely, single-cell RNA-Seq (scRNA-Seq) can be used to investigate the subtle but crucial differences in transcriptomic landscape that differentiate cellular state. Populations of cells that possess very similar gross cellular phenotypes might have remarkably different transcriptome profiles at the single-cell level due to stochastic transcription events, unsynchronized cell cycle stages, or inherent biological heterogeneity (Grün and van Oudenaarden 2015) . Therefore, the normalization methods, statistical design models, and clustering methods of standard expression profiling may not work well for cell populations that cover wide ranges of cell types or conditions. One major concern in the analysis of scRNA-Seq datasets is the increased levels of noise in the measured transcript abundances per cell.
Excessive transcript dropout rates and stochastic bursting events in scRNA-Seq data create abundant non-detections, high variability, and complex expression distributions in the data as compared to bulk RNA-Seq. Therefore, it is important to distinguish low-quality, high-noise samples that are poorly amplified or degraded during library preparation. Optimal transcript normalization methods also differ for scRNA-Seq datasets as compared to typical bulk analyses. The mRNA content and capture efficiency can vary over a wide range between individual cells, the effects of which can be mitigated through the use of spike-in control molecules that can be used to model technical noise and as a function of transcript abundance (Brennecke et al. 2013; Ding et al. 2015) .
Following normalization and quality control procedures, the next step in scRNASeq analysis often involves clustering of the samples to identify a set of gene markers that can segregate cells into distinct groups. Most published scRNA-Seq studies have used gene filtering and feature selection methods developed for bulk RNA-Seq, such as calculating the most variable genes (Klein et al. 2015; Macosko et al. 2015 ) the most significantly differentially expressed genes between known cell types (Shalek et al. 2013) , or genes that have high contribution to the first few principal components Li et al. 2016 ). This candidate set of marker genes is then used to identify subpopulations of cells via standard clustering methods, such as hierarchical clustering, k-means clustering, or principal component analysis (PCA).
Visualization of these datasets using principal component analysis (PCA) or t-distributed stochastic neighbor embedding (t-SNE) (Maaten and Hinton 2008) can provide qualitative information about the number of clusters present and relative levels of cluster heterogeneity, but does not give a quantitative estimate of how many clusters are present nor whether a given sample belongs with one cluster or another. Proper choice of a clustering algorithm might depend upon the biological context of the samples. For example, most published single-cell clustering tools are optimized either for mixed populations of distinct cells (Kharchenko et al. 2014; Grün and van Oudenaarden 2015; Haghverdi et al. 2015; Satija et al. 2015; Xu and Su 2015; Zeisel et al. 2015b) or for time-series datasets that assume a smooth distribution from one cell type to another (Bendall et al. 2014; Marco et al. 2014; Trapnell et al. 2014; Setty et al. 2016) . In practice, datasets can often include a mixture of cells from distinct cell types as well as related sub-clusters with significant overlap. Having a quantitative estimate of the relative similarity of each cell to each cluster centroid can be useful in these scenarios.
Here we present an integrated analysis tool that aims to facilitate the analysis of single-cell RNA-Seq data, addressing the challenges outlined above. Our Singlecell RNA-Seq Analysis and Klustering Evaluation (SAKE) method provides several modules that include: data pre-processing for quality control, sample clustering, t-SNE visualization of clusters, differential expression between clusters, and functional enrichment analysis. We applied SAKE to four recently published single-cell datasets with very different experimental designs (Deng et al. 2014; Ting et al. 2014; Zeisel et al. 2015a; Goolam et al. 2016 ) and evaluate its performance by the ability to correctly identify clusters reported in these studies. We also provide a comparison of SAKE performance on these datasets to multiple available scRNA-Seq analysis tools that have demonstrated rigorous performance in published studies: SINCERA, SEURAT, and SC3. We show that most scRNA-Seq analysis tools perform similarly for a wide range of sample types, despite each being algorithmically independent. In particular, SAKE performs similarly in most of these studies, and performs best for the Zeisel et al study that included a large, complex mixture of cells with extensive substructure.
Importantly, SAKE also includes quantitative statistics to evaluate the clustering results, a feature missing from most other methods.
After demonstrating the success of the SAKE analysis package, we applied this method to better understand the mechanisms by which human melanoma cells respond to targeted inhibitors of the BRAF oncogene. Resistance to targeted BRAF inhibitors is widespread and presents a barrier to its efficacy as a therapeutic, since a large fraction of melanoma tumors initially respond to BRAF inhibition, but nearly all patients rapidly develop resistance (Müller et al. 2014; Shi et al. 2014; Sun et al. 2014; Perna et al. 2015) . We used two single cell RNASeq platforms, Fluidigm C1 and 10x Genomics, to follow thousands of individual melanoma cells that have developed resistance to targeted BRAF inhibitors.
Several published studies have identified validated gene markers of resistance to BRAF inhibitors, predominantly from bulk cell extracts, with often conflicting 6 results that depend upon cellular context (Villanueva and Herlyn 2008; Villanueva et al. 2010; Konieczkowski et al. 2014; Sun et al. 2014; Ji et al. 2015; Verfaillie et al. 2015; Shaffer et al. 2017) . We show that SAKE recapitulates several of these known markers as well as identifying novel markers of resistance that appear in rare populations of pre-resistant cells present in the population prior to drug application. In addition to these markers of "intrinsically resistant" cells, SAKE also identifies several genes that appear to mark a transient state between cells that are fully sensitive to BRAF inhibitors and fully resistant, as recently suggested in a study using single molecule FISH to evaluate resistance markers in melanoma cell populations (Shaffer et al. 2017) . By integrating single-cell genomic and transcriptomic data, we show that this transiently resistant state can emerge from many clonal lineages present in the population prior to drug application. Together, these results suggest that many avenues of escape are available to melanoma cells responding to targeted inhibitors, and that the state of the cells prior to drug application can be an important determinant of which avenue is taken.
Results

Workflow for analyzing single-cell RNA-Seq data with SAKE
Single-cell RNA-Seq datasets contain both rich information as well as inherent technical artifacts. The SAKE workflow is designed to robustly categorize gene expression profiles while avoiding unwanted noise (Fig. 1A) . Following the The core of the SAKE clustering algorithm is a module to identify clusters via Non-negative Matrix Factorization (NMF) (Gao and Church 2005; Kim and Park 2007) . NMF has successfully been used to identify molecular subtypes in bulk RNA-Seq expression profiles in many contexts (Hoadley et al. 2014; Weinstein et al. 2014; Moffitt et al. 2015 Once an optimal number of clusters, k, has been determined, SAKE next performs a larger number of iterations of the NMF algorithm with fixed k, in order to robustly estimate the likelihood that each sample belongs to a given cluster and the relative importance of each marker gene in determining cluster
membership. An example heat map of the cluster membership likelihood calculations for a particular N by k factorization of a gene expression matrix is shown in Fig.1B (applied to the dataset of (Treutlein et al. 2016) , described in detail in the supplemental section). In Fig. 1B (Fig. 1D ). Differential expression analysis between clusters can be evaluated using standard tools such as the DESeq2 algorithm (Love et al. 2014) . Results are displayed for DE genes across NMF groups together with
RefSeq annotation and Type-1 error corrected statistics (Fig. 1D) . Moreover, GO Term enrichments and GSEA allow for the identification of functional categories enriched in each NMF cluster (Fig. 1E) , which can serve as guidance for further investigation and follow up studies.
A detailed tutorial for using the SAKE analysis package is provided in the Online
Methods and supplementary material. In addition to providing the code as an open source repository on Github, we present R markdown documents that allow for instructions, commands, and results to be presented together.
Evaluation of SAKE on published data sets
We measured the success of the SAKE pipeline by its ability to reproduce the major findings from recently published scRNA-Seq studies that used a variety of analysis methods for cluster identification ( Fig. 2A) Normalized mutual Information (NMI) was used to compare the performance of each method on four published datasets in terms of the ability to recapitulate cluster assignments as given by the initial publication. Error bars were measured by subsampling 90% of the cells from each dataset and iterating 1000 times to ensure robust results. between each of these three algorithms in terms of the methods used for gene feature selection and clustering. For comparison, we also include the results for a "simple" analysis that includes identifying the number of clusters, k, via a t-SNE projection plot, and then running a k-means clustering algorithm to assign samples to each of those k clusters (Fig. 2B) .
To evaluate the robustness of these results, we randomly selected 90% of the samples for each of the published studies and performed 100 iterations of cluster identification for all of the compared clustering methods. In each iteration, we calculated the normalized mutual information (NMI) and adjusted rand index given cluster is largely similar for each of these algorithms, it is worth noting that SAKE is unique in providing quantitative metrics for the estimated number of clusters present, for the assignment of each sample to a given cluster, and for the relative ability of each gene to act as a marker for cluster membership.
Application of SAKE to human Melanoma cell lines
Having demonstrated the success of the SAKE algorithm on published datasets, we next applied the SAKE method to questions that can best be answered by To test whether these markers enriched in resistant populations can be generalized to other contexts, another human melanoma cell line with the same V600E mutation, A375, was selected and sent out for sequencing after deriving resistant populations following the same experimental procedure (Supplemental Table S1 ). After combining data from 451Lu and A375, melanoma signature gene sets (Hoek et al. 2008; Widmer et al. 2012; Verfaillie et al. 2015) were used as input for sample clustering (Fig. 3C ). In general, the samples clustered first by their cell line instead of their treatment conditions.
Differential gene expression analysis also showed that there was minimal overlap between the two cell lines in terms of shared genes that marked BRAFi resistant cells (Supplemental Fig. 2C ), suggesting that these two cell lines that shared the same driver mutation might be using different pathways to enable growth in the presence of BRAF inhibitor molecules. One possible explanation is that these two cell lines possess unique expression profiles despite sharing the same genomic V600E BRAF driver mutation, and that these expression states contribute more to the overall transcriptome landscape than do the genes that drive resistance to BRAFi. To test that hypothesis, we would need to determine if our melanoma samples are derived from two distinct melanoma molecular subtypes, marked by their expression profiles, that generalize to additional samples.
Recent results from the Cancer Genome Atlas Consortium have described multiple transcriptome subtypes in melanoma patient tumors (The Cancer Genome Atlas Network 2015), similar to the "subtypes" that have previously been described for breast cancer and others (Hoadley et al. 2014) . Indeed, like breast cancer subtypes, the melanoma cancer subtypes, dubbed "proliferative,"
"invasive," and "immune-infiltrated," also correlate with overall patient survival rates. Moreover, these subtypes appear to be independent of driver mutations, since no enrichment was seen between the most common melanoma driver mutations (in BRAF, NRAS, and others) and transcriptome subtypes (The Cancer Genome Atlas Network 2015). We first used the SAKE algorithms, which work both for bulk and single-cell RNA-seq data, to determine whether we can reproduce these transcriptome subtype results on the TCGA datasets. Results from our SAKE analysis of TCGA data showed three groups with distinct biological functions and survival outcome that largely overlapped with the previously published findings. Supplemental We next set out to determine whether these TCGA-derived melanoma subtype markers would also be present in cell culture samples, like the A375 and 451Lu cell lines described above. The markers of infiltrating immune cells were not expected in cell culture models, which was confirmed by very low expression of immune cell markers in the CCLE cell line data. Accordingly, the markers identified by SAKE in proliferative and invasive subtypes were used to classify a panel of Melanoma samples from the Cancer Cell Line Encyclopedia (CCLE).
Indeed, 451Lu and A375 expression profiles were classified into the "proliferative" and "invasive" subtypes, respectively (Supplemental Fig. S3C ).
Each of the remaining CCLE cell lines also fell cleanly into one of these two groups. Moreover, BRAFi resistant cells from each of the 451Lu and A375
subtypes also remained within the same subtype as their respective parental cell lines, suggesting that subtype switching was not a dominant feature of BRAFi resistant cells (Supplemental Fig. S3C ). Having confirmed that these melanoma transcriptome subtypes are present in both TCGA patient samples as well as the cultured cell lines described above, we next sought to determine whether these expression profiles would be faithfully represented by each individual cell in the population. Conversely, "subtype" might represent an averaging over many distinct cellular states that was not wholly present in any one cell. To answer this question, we would need to characterize the expression profiles of hundreds to thousands of melanoma cells from each subtype.
SAKE Identifies Four Major groups in Fluidigm/Smart-Seq Datasets
Single-cell RNA-Seq data was prepared from both the A375 and 451Lu cell lines using the Fluidigm C1 system to isolate cells, convert mRNA to cDNA, amplify cDNA and single-cell libraries were generated using the Illumina Nextera XT kit.
We isolated around 100 cells from each of the four conditions (A375-Par, A375-BR, 451Lu-Par, and 451Lu-BR). On average, more than 10,000 transcripts were detected per library (Supplemental Table S2 ). These C1 scRNA-Seq datasets were first mixed with the bulk data to evaluate the quality of the sequencing results in terms of transcript coverage. Signature gene sets that mark proliferative and invasive subtypes were used for clustering (Hoek et al. 2008 ).
Most single cells recapitulated a similar expression pattern as that seen in the bulk RNA-Seq data and did not display a single-cell platform-specific profile (Supplemental Fig. S4A ). Moreover, the similarity of the single-cell and bulk expression patterns suggest that the melanoma subtype profiles seen in bulk datasets are also representative of the dominant expression patterns of individual single cells. Additionally, the BRAFi resistant cells from both the A375 and 451Lu populations appear to remain within their molecular subtypes regardless of sensitivity to BRAFi treatment, as was seen for the bulk transcriptome profiles.
Thus, response to BRAFi treatment may be constrained by molecular subtype, but the subtype markers cannot be used to explore BRAFi driven expression changes.
To explore the gene expression alterations associated with resistance to BRAFi, we next applied the SAKE algorithm to all ~400 cells from each of the A375 and 451Lu parental and resistance populations. A t-SNE projection of these results can be seen in Fig. 3D . 4B ). The SAKE identified groups largely overlapped with the populations from which these cells derived (Fig. 3D) , with little statistical evidence for isolated subclusters within each of the four populations. We did not observe a direct correlation between these four SAKE identified groups and cell cycle stages (Supplemental Fig. 4C ). However, there were some deviations from these general trends. First, a small fraction of the cells in the parental cell lines appeared to exhibit markers of the resistant populations and, conversely, a small fraction of the cells isolated from the resistant populations appeared to still express parental markers as can be seen on the t-SNE plot of Fig. 3D and the heatmap of Fig. 3E . In addition, the t-SNE plot shows some sub-clustering within the A375-BR population, but these differences were not robust enough to represent a statistically robust independent population.
We next turned to ask whether any of the cell populations showed more or less heterogeneity in expression markers either before or after selection for resistance to BRAF inhibitors. Qualitatively, the heatmap of 
High throughput sparse 10x libraries for rare cell identification
To show that the results from the Fluidigm/Smart-Seq libraries were not singlecell RNA-Sequencing method-specific, we chose to sequence the same cell line using a different method. We selected the 451Lu parental and resistant populations for higher throughput profiling on the Chromium Single Cell 3' Solution from 10x Genomics, which provided information for many more cells with shallower coverage (Supplemental Table S2 ). Transcripts from ~6500 single cells from the 451Lu parental and resistant populations were uniquely barcoded and sequenced, and PCR duplicates were removed using unique molecular identifiers (UMI). UMI counts for each cellular barcode were quantified and used to estimate the number of cells successfully captured and sequenced. On average, we obtained ~90,000 reads per cell and more than 5000 expressed genes in each cell (Supplemental Table S2 ). The Cell Ranger Single-Cell Software suite was used for demultiplexing, barcode processing, alignment, and initial clustering of the raw scRNA-Seq profiles. We first used t-SNE projection maps to get a general overview of the sequencing results, as displayed in Fig.   3G . In the 451Lu parental cells, the majority of the cells fell into a single extended cluster, while two outlier groups formed unique subpopulations that were isolated and distinct from the rest of the parental population. These small isolated groups represented cells with extremely low or high transcript coverage rates, according to their UMIs, and were removed from further analysis. Cells from the 451Lu resistant population formed a single group and did not have a clear separation into isolated sub-populations or distinct mixing with the parental population (Fig.   3G ).
The sequencing depth and the number of expressed transcripts detected from the 10x data showed more variance as well as lower overall transcript coverage than the Fluidigm/Smart-Seq data (Supplemental Table S2 ), as expected from the lower total read counts sequenced per cell. To assess whether we could combine and compare these two types of data, we used the Nearest Shrunken Centroids method (Tibshirani et al. 2002) to calculate centroids from each population separately for parental and resistant cells, using only 10x-specific DE genes, assuming that genes detected in this shallow survey would be present in both Fluidigm C1 and 10x Genomics data (Fig. 3H) . Briefly, the centroid of the expression patterns for each of the parental and resistant populations was calculated to obtain a median expression pattern for that population across all genes present in the 10x dataset. Spearman rank correlations were then used to score the distance of all cells in the sample from these centroids and this distance was the score for how "BR-like" or "Parental-like" each cell appeared (additional details are given in Supplemental Materials). Results from both the C1 and 10x data could then be displayed together (Fig 3H) , and indicated that the cells largely separated according to their cell-type specific scores, and that most cells from each platform fell cleanly into one category or another. Moreover, the fraction of cells that showed equivalent scores for both parental and resistant profiles was similar across both the C1 and 10x platforms (Supplemental Methods). In addition, we compared the differentially expressed genes between the BRAFi resistant and parental cells for both C1 and 10x data and identified a largely similar set of commonly altered genes (Supplemental Fig. S5A -E),
indicating that the two platforms give largely comparable results. As a result, the high degree of concordance between these two data sets shows that the findings correspond well to each other, with little platform-dependent effects beyond sequencing depth and the ability to identify rare cells in larger populations.
DCT marks cells with intrinsic resistance in 451Lu melanoma cells
In the t-SNE project map of the C1 dataset (Fig. 3D) , a small number of 451Lu-Par cells can be seen located near the 451Lu-BR population and distinct from the rest of the 451Lu-Par populations ( Fig. 3D-E) . We wanted to test whether these rare parental cells that are exhibiting similar transcriptomic profiles to BRAFi resistant cells would also display less sensitivity to the BRAFi drug treatment.
This would be consistent with an intrinsically resistant population already present in the parental cells.
We first used a standard differential expression analysis method, DESeq2, to determine the list of statistically enriched genes between the parental and resistant 451Lu for C1 data, requiring two-fold mean expression changes and a p-value less than 0.05 (Fig. 4A ). In addition, we used the default method that was implemented in the 10x Cell Ranger suite to identify differentially expressed genes in the 10x data. Checking through the list of genes that were identified as significantly differentially expressed by both DESeq2 and Cell Ranger, we saw highly variable levels of gene expression among these genes across resistant samples (Supplemental Fig. S5B-C) . Therefore, we used SAKE to help identify genes more stably expressed in resistant populations from both Fluidigm C1 and 10x data sets. These SAKE markers have distinct expression distributions across parental and resistant populations, but highly stable expression within each population (Supplemental Figure S6A-B) . Moreover, genes identified by both SAKE and DESeq2/Cell Ranger methods formed a high confidence candidate list for follow up validation studies (Supplemental Table S3 ).
We then searched through these genes for cell surface markers that could be used to isolate cells. DCT was one of the highest confidence candidates that showed a distinct but consistent expression pattern between parental and (Fig. 4D , left panels). Following treatment, the remaining cells can be seen to largely be DCT positive (Fig. 4D, right panels) . As a positive control, most cells from the derived resistant 451Lu population express high levels of DCT. These results are quantified and summarized in Fig. 4E .
We additionally checked a list of previously published genes that have been identified as associated with resistance to BRAF inhibitors. Surprisingly, most of these genes did not show a binary pattern similar to DCT, with dominant expression in one of the two populations ( Fig. 4G-H) . Instead, most of these published resistance marker genes showed a curious pattern of expression that was most differential at the interface between the two populations (Supplemental Fig. S7 ). While we did not see enrichment for these markers in any isolated outlier groups, these markers were enriched at the tip of the parental population that was proximal to the resistant populations as well as at the tip of the resistant population that was proximal to the parental cluster. These results would be consistent with a transient population between the two fully drug sensitive and fully resistant states.
We then ran SAKE on these 10x data to determine whether SAKE would also identify the presence of this unique "cluster" of candidate transient cells based
solely on their transcriptional profile without any prior knowledge from the marker lists (Supplemental Fig. S7 ). SAKE reported 3 major clusters from the entire 10x dataset, which were the parental cells, resistant cells, and a new population of cells that sat at the interface between these two major clusters on the t-SNE projection maps ( by Shaffer et al., (2017) ; this supports the hypothesis that some melanoma cells acquire resistance by transiting through a transient "pre-resistant" state marked by high levels of MAPK pathway genes such as EGFR and AXL, but that the expression of these genes is not required for the maintenance of a stably resistant population. In addition, SAKE identified several additional genes that mark this candidate "transitional" population, which are given in Supplemental Table S4 . While these cells do not occupy an isolated sub-cluster on the t-SNE projection map, the SAKE algorithm did identify this population as a robust subcluster, highlighting the success of SAKE at finding small sub-populations in high dimensional data.
To garner additional support for the hypothesis that these cells represent a transient transcriptional state that can seed the resistant population, we also generated genomic copy number data to compare to the transcriptome data.
Integrating both RNA expression data and genomic CNV data would allow us to determine whether particular subsets of the population with similar expression patterns were also more likely to share CNV mutational patterns, as might be expected through simple selection for genetic mutations. Conversely, if many cells with highly divergent CNV mutational patterns nonetheless shared very similar transcriptional patterns, one would expect that the "transitional" expression state might be due to additional factors that could reflect epigenetic or gene regulatory modifications. This is conceptually similar to the Luria-Delbrück fluctuation analysis that was performed in the Shaffer et al., (2017) study to demonstrate that resistance to BRAFi treatment in their cells could be due to non-heritable effects arising stochastically among cells from several clonal populations (Shaffer et al. 2017) . If random genetic mutations were giving rise to resistant cells in this scenario, one would expect that a small number of cells would spontaneously develop resistance, and that these cells may display distinct genomic mutations patterns while potentially displaying shared transcriptomic patterns.
To check whether this phenomenon holds true in our 451Lu melanoma data, we first performed copy number variation (CNV) analysis from the scRNA-Seq data, as has been described previously (Patel et al. 2014; Tirosh et al. 2016) . Briefly, genes were binned into sliding windows containing 100 consecutive genes, to ensure that the alterations due to differential expression patterns would be averaged out over a large enough region such that very large CNVs could be detected independent of expression differences. In addition, 100 karyotypically normal Human 293T cells with scRNA-Seq profiles of approximately the same depth were used to derive the baseline reference for calibrating relative CNV calls and to validate that this method would not incorrectly call CNV patterns in karyotypically normal data (Fig. 5B) . To ensure that the CNV profiles we inferred using this method match what would have been found as directly measured from the DNA, we additionally isolated DNA from bulk cell populations from each of the parental and resistant populations and generated DNA libraries directly (Supplemental Table S4 ). We found a high degree of concordance between the CNV profiles derived from the scRNA-Seq data and the bulk DNA-Seq data (Fig.   5B,D) . This suggested that the thousands of cells sequenced using the scRNASeq protocol could also be used as proxy to infer clonal CNV relationships.
The inferred CNV patterns showed two major clones that corresponded to the parental and resistant cell populations. Depletions on chr9p and amplifications on chr1p, chr7p, chr11q, chr20q, and chr22q were signatures for the resistant cells, and these large regions of genomic alterations match what has been reported in other CNV profiles using bulk melanoma samples (Beroukhim et al. 2010 ).
Beyond the two dominant clones, these cells were further classified into 8 subgroups, or "clonal lineages." However, none of these 8 subgroups of cells showed an enrichment for the cells that are identified as having the "transitional" transcriptome patterns (yellow bars in Fig. 5B ), which could be found in several of the 8 subgroups. This suggested that these cells were derived from several unrelated clonal lineages, and were likely not derived from a single strictly heritable lineage. This is consistent with the hypothesis that non-genetic effects contribute to the acquisition of resistance to BRAF inhibitors in melanoma cells, and is consistent with previous reports (Shaffer et al. 2017; Sharma et al. 2017) .
Discussion
Methods developed for bulk RNA-Seq data analysis (Anders and Huber 2010; Robinson et al. 2010; Dillies et al. 2013; Love et al. 2014) can be adapted for application to scRNA-Seq data, but need to be tailored to address the specific issues inherent in working with noisy, low-coverage, heterogeneous sample sets.
We present a processing and analysis pipeline for single cell RNA-Seq datasets, SAKE, that is designed to look for quality control issues specific to scRNA-Seq Having verified the success of SAKE on several published scRNA-Seq datasets, we next applied this method to uncover the transcriptional alterations that occur as melanoma cells develop resistance to targeted inhibitors of the BRAF oncogene. Single cell transcriptomes were obtained from both a low-throughput high-depth method (Fluidigm C1, ~100 cells per group) as well as a highthroughput shallow sequencing technology (10x genomics, ~3500 cells per group). The expression profiles and typical melanoma specific marker levels were very similar between these two datasets. Overall, these two sequencing technologies provided highly concordant results, suggesting that platform-specific effects did not dominate the results.
Identification of rare "intrinsically resistant cells"
The datasets from the Fluidigm C1 and 10x platforms were combined to identify statistically differentially expressed genes between the 451Lu parental and resistant populations. Those genes that were highly abundant in the 451Lu resistant cells, with much lower overall expression in the 451Lu parental population, formed a candidate list of resistance marker genes. We next sought to determine whether rare cells in the parental population might be expressing these candidate resistance markers. We validated one novel resistance marker gene, DCT, with high expression in the majority of the BRAFi resistant cells and low expression in 99% of the parental population. Using a fluorescent antibody for DCT, these rare DCT positive cells were sorted from the parental population and challenged to determine sensitivity to BRAFi treatment. Consistent with DCT marking cells that are more likely to be resistant to BRAFi treatment, the DCT positive population showed reduced sensitivity to BRAFi challenge. While one report identified DCT as a potential marker for general resistance to radiotherapy (Pak et al. 2004 ), DCT has not previously been evaluated for its role in resistance to targeted inhibitors or specifically BRAF inhibitors.
Cell type specific markers for conferring resistance
Surprisingly, most of the genes that have been identified in previous studies to confer resistance to BRAFi treatment in melanoma did not show a similar expression pattern to DCT. That is, most of these genes did not show an overall binary distribution with high levels in most resistant cells and low expression in most parental cells or vice versa. Instead, a large fraction of these genes showed differential expression just at the boundary between the parental and resistant populations. This expression pattern could be consistent with previously proposed models that suggest a transitional cellular state dubbed "pre-resistance" in which cells transiently express these markers as they develop resistance to BRAF inhibitors (Shaffer et al. 2017; Sharma et al. 2017 ), but do not necessarily continue marker expression once resistance is stably established. In this model, one might expect cells with shared transcriptomic patterns, marking the transitional state, to not necessarily share genomic mutational patterns. While previous studies have used Luria-Delbruck analysis to infer the presence of multiple clones with non-heritable resistance patterns (Shaffer et al. 2017) , having direct evidence for distinct mutational patterns among cells with shared transcriptomes would extend support for this model.
Integrating genomic and transcriptomic data to infer lineage
Integrating genomic mutational information allows for an explanation of the clonal relationship of the cells that were selected for resistance to BRAF inhibitors. If most cells in the resistant population appear to be more genetically similar than the cells in the parental population, this would imply a bottleneck scenario where a small number of clones were selected. On the other hand, if resistance arises stochastically in many genetically distinct clones, this would imply that nongenetic mechanisms could be contributing to the development of drug resistance.
Our data seem to support a contribution from both mechanisms. Specifically, the intrinsically resistant DCT positive cells likely mark a small number of clonally related cells that were innately resistant to BRAFi treatment prior to drug application, and which were simply selected from the population. However, most of the previously published melanoma markers appear to be expressed in a small number of cells from both the parental and resistant populations, and these cells seem to cluster in a similar expression space on the t-SNE projection maps. This particular pattern could be consistent with a model in which clonally unrelated cells stochastically develop expression patterns that allow them to survive in the presence of inhibitors. This model would imply a non-heritable mechanism for acquired resistance that would derive from multiple clonal lineages rather than a small number of selected clones. Integrating genomic CNV and RNA-Seq information showed that the candidate "transitional" cells appear to derive from many distinct clonal lineages, and showed no enrichment for any particular clonal lineage. Moreover, cells with very distinct expression patterns were also present within the same clonal lineage, suggesting that the transitional expression pattern was not clonally inherited. These results highlight the complexity of melanoma cell populations and the multiple mechanisms available to respond to targeted inhibitor therapies.
Materials and Methods
Cell Culture
Parental cell lines A375 and 451Lu were cultured in DMEM media supplemented with 10% FBS and 1% Pencillin-Streptavadin. Resistant cell lines A375-Br15 and 451Lu-Br3 were cultured in DMEM media supplemented with 10% FBS, 1%
Pencillin-Streptavadin and 1uM of BRAF inhibitor, PLX4720. PLX4720 was obtained from Selleckchem (Catalog No.S1152).
RNA-Seq library preparation for bulk melanoma cell samples
Total RNA was extracted from approximately 10^6 freshly collected melanoma cells following standard Trizol RNA extraction protocols. RNA-seq libraries were prepared from 500ng of total RNA using the Illumina Tru-seq Stranded Total RNA kit. Libraries were barcoded and pooled in order to obtain a minimum of ~40 million reads per library on the Illumina HiSeq 5000 platform. 
RNA-
Normalized mutual information
For the published datasets we chose to evaluate the performance of clustering tools, the normalized mutual information (NMI) is calculated to compare the similarity between the SAKE (and other tools) clustering results and the published cell-labels. To calculate NMI, we first construct confusion matrix and derive accuracy and precision from it. By counting the number of overlapping points for each pair of clusters between C(r) and C(g), we can construct a summary table. The mutual information can be calculated via:
where p(x,y) is the joint probability distribution function of X and Y, and p(x) and p(y) are the marginal probability distribution functions of X and Y respectively. The normalized mutual information can then be calculated by accounting for the entropy in each of X and Y. First, entropy of a cluster w where: c is a classification in the set C of all classifications. is probability of a data point being classified as c in cluster w. Then, normalized mutual information (NMI):
Benchmark comparison
For all the published datasets we tested, we used the original processed gene expression matrix provided by the authors (Figure. 2a ). For data that contained raw read counts, we divided each column by the "total library size" scaling factor to account for differences in sequencing depth, which provide us with reads per million (RPM) value. Log transformations were then applied to the gene count table with a pseudo count of 1.
For each method, we varied the clustering parameters to obtain the optimal clustering results obtainable by each method, as described by the authors in the initial publication and as measured by concordance with the validated results presented in each publication. For t-SNE + k-means, gene filters using median absolute deviation (MAD) or custom filtering criteria were applied. Rtsne (version 0.13) package was used with the default parameters. We used the k reported by the original authors as the input for k-means clustering to identify the specific number of clusters. For SC3 (version 1.5.2), we followed the instructions in the package for gene filtering and clustering. For SINCERA, we used the z-score normalization and automatic cluster identification as described in the original publication. For SEURAT (version 1.4.0.12), we performed t-SNE embedding with the default parameters once and then clustered the data using the DBSCAN algorithm several times, for which we varied the density parameter G in the range of 0.6-3 to find a maximal NMI and reported that number in the summary table.
Data availability
All melanoma data generated in this study have been deposited in the Gene Expression Omnibus (GEO) database under accession code GEO108397 and 
